Norris Medicines

{
  "main_header": {
    "sid": 210607,
    "name": "Norris Medicines",
    "stock_name": "Norris Medicines",
    "full_name": "Norris Medicines Ltd",
    "name_url": "stocks-analysis/norris-medicines",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "16.50",
    "chg": 0.5,
    "chgp": "3.12%",
    "dir": 1,
    "prev_price": "16.00",
    "mcapval": "16.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524414,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 4,
    "sector_id": 79,
    "indexname": "India SENSEX",
    "isin": "INE744C01029",
    "curr_date": "Aug 12, 01:45 PM",
    "curr_time": "13:50 PM",
    "last_traded_at": "Aug 12, 01:45 PM IST",
    "bse_nse_vol": "924 ",
    "exc_status": "Active",
    "traded_date": "Aug 12, 2026",
    "traded_date_str": "2026 08 12",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/norris-medicines-210607-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Norris Medicines Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/norris-medicines-ltd-downgraded-to-strong-sell-amid-mixed-financial-and-technical-signals-4139398",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NorrisMedicines_mojoScore_4139398.png",
        "date": "2026-08-06 08:32:45",
        "description": "Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026. This revision follows a comprehensive reassessment of the company’s quality, valuation, financial trends, and technical indicators, reflecting a cautious outlook despite some recent positive financial results."
      },
      {
        "title": "Norris Medicines Ltd Upgraded to 'Sell' as Technicals Improve Amid Lingering Fundamental Concerns",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/norris-medicines-ltd-upgraded-to-sell-as-technicals-improve-amid-lingering-fundamental-concerns-4133071",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/8/NorrisMedicines_mojoScore_4133071.png",
        "date": "2026-08-03 08:13:15",
        "description": "Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating upgraded from Strong Sell to Sell as of 31 July 2026. This change reflects a nuanced shift in the company’s technical outlook, even as fundamental concerns persist. The upgrade is primarily driven by improvements in technical indicators, while valuation and financial trends continue to weigh on investor sentiment."
      },
      {
        "title": "Golden Cross Forms in Norris Medicines Ltd — On a Day the Stock Fell 3.8%. What the Mixed Signals Mean",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-ltd-forms-golden-cross-signalling-potential-bullish-breakout-4130569",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NorrisMedicines_goldencross_4130569.png",
        "date": "2026-07-31 18:00:17",
        "description": "The 50-day moving average has crossed above the 200-day moving average for Norris Medicines Ltd, signalling a golden cross on 31 Jul 2026. Yet, the stock declined 3.78% on the same day, while monthly momentum indicators remain bearish. This divergence between the moving averages and price action calls for a detailed examination of the signal's reliability."
      },
      {
        "title": "Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 19.63",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-ltd-hits-new-52-week-high-at-rs1963-4093177",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/7/NorrisMedicines_priceRelatedfactors_4093177.png",
        "date": "2026-07-08 09:41:59",
        "description": "With a decisive surge to Rs 19.63 on 8 Jul 2026, Norris Medicines Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical signals and sustained price momentum over the past week."
      },
      {
        "title": "Why is Norris Medicines Ltd falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-norris-medicines-ltd-fallingrising-4064868",
        "imagepath": "",
        "date": "2026-06-20 01:17:25",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Short-Term Gains Contrasted with Recent Weekly Decline</strong></p>\n<p>While the stock price has increased by 3.7% in the latest session, the weekly return data reveals a slight decline of 0.78% over the past seven days. This contrasts with the Sensex benchmark, which gained 1.69% during the same period. The recent rise in the share price may be attributed to intra-week volatility or specific market interest, but it does not yet reflect a sustained weekly uptrend.</p>\n<p><strong>Monthly Performance Outpaces Benchmark</strong></p>\n<p>Over the last month, Norris Medicines Ltd has delivered a robust return of 7.28%, significantly outperforming the Sensex’s 2.13% gain. This suggests that the company has attracted investor attention and capital inflows in the near term, possibly due to sector-spe..."
      },
      {
        "title": "Are Norris Medicines Ltd latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-norris-medicines-ltd-latest-results-good-or-bad-4024820",
        "imagepath": "",
        "date": "2026-05-31 19:21:58",
        "description": "Norris Medicines Ltd's latest financial results for Q4 FY26 present a complex picture of operational performance. The company reported a net profit of ₹0.05 crore, a notable recovery from a loss in the same quarter last year. However, this profitability comes amidst significant revenue challenges, with net sales declining to ₹1.41 crores, representing a substantial decrease of 48.16% year-on-year and a dramatic 56.88% drop from the previous quarter.\n\nThe operating margin showed a remarkable improvement, rising to 21.99% compared to just 2.57% in Q4 FY25, indicating effective cost management despite the revenue contraction. This margin expansion raises questions about the sustainability of profitability, as it appears primarily driven by cost containment rather than revenue growth.\n\nThe company's financial position remains precarious, with a negative book value of ₹14.98 per share, reflecting accumulated los..."
      },
      {
        "title": "Norris Medicines Q4 FY26: Micro-Cap Pharma Trader Posts Surprise Profit Amid Severe Revenue Decline",
        "link": "https://www.marketsmojo.com/news/result-analysis/norris-medicines-q4-fy26-micro-cap-pharma-trader-posts-surprise-profit-amid-severe-revenue-decline-4024450",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/5/NorrisMedicines_quaterlyResult_4024450.png",
        "date": "2026-05-30 23:46:37",
        "description": "Norris Medicines Limited, a micro-cap pharmaceutical trading and distribution company, reported a net profit of ₹0.05 crores for Q4 FY26 (January-March 2026), marking a dramatic reversal from the ₹0.23 crore loss recorded in the same quarter last year. However, this profitability came against a backdrop of severe revenue contraction, with quarterly net sales plummeting 48.16% year-on-year to ₹1.41 crores. The company's shares, trading at ₹13.25 with a market capitalisation of just ₹14.00 crores, remain under significant pressure as investors grapple with the sustainability of this turnaround."
      },
      {
        "title": "When is the next results date for Norris Medicines Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-norris-medicines-ltd-4015276",
        "imagepath": "",
        "date": "2026-05-26 23:20:44",
        "description": "The next results date for Norris Medicines Ltd is scheduled for 30 May 2026...."
      }
    ],
    "total": 261,
    "sid": "210607",
    "stock_news_url": "https://www.marketsmojo.com/news/norris-medicines-210607"
  },
  "announcements": [
    {
      "caption": "Board Meeting Intimation for Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended June 30 2026",
      "datetime": "08-Aug-2026",
      "details": "Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2026 inter alia to consider and approve Unaudited Financial Results for the Quarter Ended 30th June 2026",
      "source": "BSE"
    },
    {
      "caption": "Announcement under Regulation 30 (LODR)-Change in Management",
      "datetime": "30-Jul-2026",
      "details": "Intimation relating to appointment of Mr. Iqubal Ismail Patel as Chief Financial Officer (CFO) & Key Managerial Personnel (KMP) of the Company in the meeting of the Board dated 30th July 2026.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Outcome Of The Board Meeting Dated 30Th July 2026.",
      "datetime": "30-Jul-2026",
      "details": "Outcome of Board Meeting held on Thursday July 30 2026 pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "",
      "data": [
        {
          "title": "BOARD MEETING",
          "txt": "14 Aug 2026"
        }
      ]
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Norris Medicines Ltd Downgraded to Strong Sell Amid Mixed Financial and Technical Signals

2026-08-06 08:32:45

Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating downgraded from Sell to Strong Sell as of 5 August 2026. This revision follows a comprehensive reassessment of the company’s quality, valuation, financial trends, and technical indicators, reflecting a cautious outlook despite some recent positive financial results.

Read full news article

Norris Medicines Ltd Upgraded to 'Sell' as Technicals Improve Amid Lingering Fundamental Concerns

2026-08-03 08:13:15

Norris Medicines Ltd, a micro-cap player in the Trading & Distributors sector, has seen its investment rating upgraded from Strong Sell to Sell as of 31 July 2026. This change reflects a nuanced shift in the company’s technical outlook, even as fundamental concerns persist. The upgrade is primarily driven by improvements in technical indicators, while valuation and financial trends continue to weigh on investor sentiment.

Read full news article

Golden Cross Forms in Norris Medicines Ltd — On a Day the Stock Fell 3.8%. What the Mixed Signals Mean

2026-07-31 18:00:17

The 50-day moving average has crossed above the 200-day moving average for Norris Medicines Ltd, signalling a golden cross on 31 Jul 2026. Yet, the stock declined 3.78% on the same day, while monthly momentum indicators remain bearish. This divergence between the moving averages and price action calls for a detailed examination of the signal's reliability.

Read full news article

Broad-Based Technical Strength Lifts Norris Medicines Ltd to 52-Week High of Rs 19.63

2026-07-08 09:41:59

With a decisive surge to Rs 19.63 on 8 Jul 2026, Norris Medicines Ltd has reached a fresh 52-week high, propelled by a confluence of bullish technical signals and sustained price momentum over the past week.

Read full news article

Why is Norris Medicines Ltd falling/rising?

2026-06-20 01:17:25

Short-Term Gains Contrasted with Recent Weekly Decline

While the stock price has increased by 3.7% in the latest session, the weekly return data reveals a slight decline of 0.78% over the past seven days. This contrasts with the Sensex benchmark, which gained 1.69% during the same period. The recent rise in the share price may be attributed to intra-week volatility or specific market interest, but it does not yet reflect a sustained weekly uptrend.

Monthly Performance Outpaces Benchmark

Over the last month, Norris Medicines Ltd has delivered a robust return of 7.28%, significantly outperforming the Sensex’s 2.13% gain. This suggests that the company has attracted investor attention and capital inflows in the near term, possibly due to sector-spe...

Read full news article

Are Norris Medicines Ltd latest results good or bad?

2026-05-31 19:21:58

Norris Medicines Ltd's latest financial results for Q4 FY26 present a complex picture of operational performance. The company reported a net profit of ₹0.05 crore, a notable recovery from a loss in the same quarter last year. However, this profitability comes amidst significant revenue challenges, with net sales declining to ₹1.41 crores, representing a substantial decrease of 48.16% year-on-year and a dramatic 56.88% drop from the previous quarter. The operating margin showed a remarkable improvement, rising to 21.99% compared to just 2.57% in Q4 FY25, indicating effective cost management despite the revenue contraction. This margin expansion raises questions about the sustainability of profitability, as it appears primarily driven by cost containment rather than revenue growth. The company's financial position remains precarious, with a negative book value of ₹14.98 per share, reflecting accumulated los...

Read full news article

Norris Medicines Q4 FY26: Micro-Cap Pharma Trader Posts Surprise Profit Amid Severe Revenue Decline

2026-05-30 23:46:37

Norris Medicines Limited, a micro-cap pharmaceutical trading and distribution company, reported a net profit of ₹0.05 crores for Q4 FY26 (January-March 2026), marking a dramatic reversal from the ₹0.23 crore loss recorded in the same quarter last year. However, this profitability came against a backdrop of severe revenue contraction, with quarterly net sales plummeting 48.16% year-on-year to ₹1.41 crores. The company's shares, trading at ₹13.25 with a market capitalisation of just ₹14.00 crores, remain under significant pressure as investors grapple with the sustainability of this turnaround.

Read full news article

When is the next results date for Norris Medicines Ltd?

2026-05-26 23:20:44

The next results date for Norris Medicines Ltd is scheduled for 30 May 2026....

Read full news article

View All News